

SAFETY DATA SHEET

1. PRODUCT

1.1 Product identifiers

Name: Sodium salicylate

CAS-No.: 54-21-7

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory chemicals, Manufacture of substances

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)

Acute toxicity, Oral (Category 4), H302

Eye irritation (Category 2A), H319

For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2 GHS Label elements, including precautionary statements

Pictogram	
Signal word	Warning
Hazard statement(s)	H302 Harmful if swallowed. H319 Causes serious eye irritation.
Precautionary statement(s)	P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/ eye protection/ face protection. P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P330 Rinse mouth. P337 + P313 If eye irritation persists: Get medical advice/ attention. P501 Dispose of contents/ container to an approved waste disposal plant.

2.3 Hazards not otherwise classified (HNOC) or not covered by GHS

No data available

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Synonyms: Salicylic acid sodium salt
2-Hydroxybenzoic acid sodium salt

Formula: $C_7H_5NaO_3$

CAS-No.: 54-21-7

EC-No.: 200-198-0

Hazardous components

Component	Classification	Concentration
Sodium salicylate	Acute Tox. 4; Eye Irrit. 2A; H302, H319	90 -100 %

4. FIRST AID MEASURES

4.1 Description of first aid measures

General advice
Move out of dangerous area. Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.2 Indication of any immediate medical attention and special treatment needed

no data available

5. FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture

Carbon oxides, Sodium oxides

5.3 Advice for firefighters

Wear self contained breathing apparatus for fire fighting if necessary.

5.4 Further information

no data available

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Avoid breathing dust.

For personal protection see section 8.

6.2 Environmental precautions

Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4 Reference to other sections

For disposal see section 13.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols.

Provide appropriate exhaust ventilation at places where dust is formed.

For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components with workplace control parameters

Contains no substances with occupational exposure limit values.

8.2 Exposure controls

Appropriate engineering controls

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

Personal protective equipment

Eye/face protection	Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection	Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. Full contact Material: Nitrile rubber Minimum layer thickness: 0.11 mm Break through time: 480 min Material tested: Dermatrill® (KCL 740 / Aldrich Z677272, Size M) Splash contact Material: Nitrile rubber Minimum layer thickness: 0.11 mm Break through time: 480 min Material tested: Dermatrill® (KCL 740 / Aldrich Z677272, Size M) data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374 If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It should not be construed as offering an approval for any specific use scenario.
Body Protection	Complete suit protecting against chemicals, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection	For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator. For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure	Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance	Form: solid
Odour	no data available
Odour Threshold	no data available

pH	6.5
Melting point/freezing point	Melting point/range: > 300 °C (> 572 °F)
Initial boiling point and boiling range	no data available
Flash point	no data available
Evaporation rate	no data available
Flammability (solid, gas)	no data available
Upper/lower flammability or explosive limits	no data available
Vapour pressure	no data available
Vapour density	no data available
Relative density	0.35 g/cm ³ at 20 °C (68 °F)
Water solubility	no data available
Partition coefficient: n-octanol/water	no data available
Auto-ignition temperature	no data available
Decomposition temperature	no data available
Viscosity	no data available
Explosive properties	no data available
Oxidizing properties	no data available

9.2 Other safety information

no data available

10. STABILITY AND REACTIVITY

10.1 Reactivity

no data available

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

no data available

10.4 Conditions to avoid

no data available

10.5 Incompatible materials

Strong oxidizing agents, Strong acids

10.6 Hazardous decomposition products

Other decomposition products - no data available

In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity

LD50 Oral - rat - 930 mg/kg
 LD50 Oral - mouse - 540 mg/kg
 LD50 Oral - rabbit - 1,700 mg/kg
 Inhalation: no data available
 Dermal: no data available
 LD50 Intraperitoneal - rat - 542 mg/kg
 LD50 Intramuscular - mouse - 760 mg/kg
 LD50 Intraperitoneal - mouse - 500 mg/kg
 LD50 Intravenous - mouse - 500 mg/kg
 LD50 Subcutaneous - mouse - 550 mg/kg
 LD50 Intravenous - rabbit - 415 mg/kg
 LD50 Intravenous - dog - 562 mg/kg

Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
Eyes - rabbit Result: Eye irritation
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH. NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP. OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.
Reproductive toxicity
no data available no data available
Specific target organ toxicity -single exposure
no data available
Specific target organ toxicity -repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available Salicylic acid and other salicylates are transferred into breast milk. Animal and human data suggest that the reduced clearance of salicylates by neonates may result in drug accumulation and toxic effects even when repeated exposures are small. Because of these concerns, the WHO Working Group on Human Lactation classified the salicylates as unsafe for use by nursing women.

12. ECOLOGICAL INFORMATION

12.1 Toxicity

Toxicity to fish	LC50 - Pimephales promelas (fathead minnow) - 1,370 mg/l - 96 h
Toxicity to daphnia and other aquatic invertebrates	No data available
Toxicity to algae	No data available
Toxicity to bacteria	No data available

12.2 Persistence and degradability

no data available

12.3 Bioaccumulative potential

no data available

12.4 Mobility in soil

no data available

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6 Other adverse effects

no data available

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION

DOT (US)

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

15. REGULATORY INFORMATION

SARA 302 Components

SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

Acute Health Hazard

Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components

Component	CAS-No.	Revision Date
Sodium salicylate	54-21-7	

New Jersey Right To Know Components

Component	CAS-No.	Revision Date
Sodium salicylate	54-21-7	

California Prop. 65 Components

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

16. OTHER INFORMATION

Full text of H-Statements referred to under sections 2 and 3.

Acute Tox. Acute toxicity

Eye Irrit. Eye irritation

H302 Harmful if swallowed.

H319 Causes serious eye irritation.

HMIS Rating

Health hazard: 2

Chronic Health Hazard:

Flammability: 0

Physical Hazard 0

NFPA Rating

Health hazard: 2

Fire Hazard: 0

Reactivity Hazard: 0
